Syntimmune's Series A - II Round

Syntimmune raised a round of funding on March 22, 2016.

Syntimmune is a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcRn).…

Articles about Syntimmune's Series A - II Round: